Detalhe da pesquisa
1.
Using Target Engagement Biomarkers to Predict Clinical Efficacy of MetAP2 Inhibitors.
J Pharmacol Exp Ther
; 371(2): 299-308, 2019 11.
Artigo
Inglês
| MEDLINE | ID: mdl-31537613
2.
Structure-based optimization of 1H-imidazole-2-carboxamides as Axl kinase inhibitors utilizing a Mer mutant surrogate.
Bioorg Med Chem Lett
; 27(4): 1099-1104, 2017 02 15.
Artigo
Inglês
| MEDLINE | ID: mdl-28082036
3.
Design and Discovery of a Potent and Selective Inhibitor of Integrin αvß1.
J Med Chem
; 2024 Jun 13.
Artigo
Inglês
| MEDLINE | ID: mdl-38872300
4.
Discovery of the Bruton's Tyrosine Kinase Inhibitor Clinical Candidate TAK-020 (S)-5-(1-((1-Acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-2,4-dihydro-3H-1,2,4-triazol-3-one, by Fragment-Based Drug Design.
J Med Chem
; 64(17): 12893-12902, 2021 09 09.
Artigo
Inglês
| MEDLINE | ID: mdl-34448571
5.
CX3CL1-Fc treatment prevents atherosclerosis in Ldlr KO mice.
Mol Metab
; 20: 89-101, 2019 02.
Artigo
Inglês
| MEDLINE | ID: mdl-30553772
6.
Chronic fractalkine administration improves glucose tolerance and pancreatic endocrine function.
J Clin Invest
; 128(4): 1458-1470, 2018 04 02.
Artigo
Inglês
| MEDLINE | ID: mdl-29504946
7.
MET Tyrosine Kinase Inhibition Enhances the Antitumor Efficacy of an HGF Antibody.
Mol Cancer Ther
; 16(7): 1269-1278, 2017 07.
Artigo
Inglês
| MEDLINE | ID: mdl-28341789
8.
Correction to "Discovery of the Bruton's Tyrosine Kinase Inhibitor Clinical Candidate TAK-020 (S)-5-(1-((1-Acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-2,4-dihydro-3H-1,2,4-triazol-3-one, by Fragment-Based Drug Design".
J Med Chem
; 64(21): 16318, 2021 Nov 11.
Artigo
Inglês
| MEDLINE | ID: mdl-34708652
9.
Biological characterization of TAK-901, an investigational, novel, multitargeted Aurora B kinase inhibitor.
Mol Cancer Ther
; 12(4): 460-70, 2013 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-23358665
10.
Target cell defense prevents the development of diabetes after viral infection.
Nat Immunol
; 3(4): 373-82, 2002 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-11919579